Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)&gt;2 m2. (Q33384061)

26 July 2017

Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. (English)

1 reference

26 July 2017

1 reference

Joanna Schwartz

1

1 reference

26 July 2017

Beth Toste

series ordinal

2

1 reference

26 July 2017

Don S Dizon

series ordinal

3

1 reference

26 July 2017

language of work or name

English

0 references

publication date

8 April 2009

1 reference

26 July 2017

1 reference

26 July 2017

114

1 reference

26 July 2017

53-56

1 reference

26 July 2017

1

1 reference

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Body size and risk of epithelial ovarian and related cancers: a population-based case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Body mass index and risk of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Effect of obesity on survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

The effect of obesity on survival in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Actual body weight for determining doses of chemotherapy in obese cancer patients: evaluation of treatment tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Undertreatment of obese women receiving breast cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.03.010

10.1016/J.YGYNO.2009.03.010

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference